The usefulness of lower urinary tract symptoms (LUTS) as mortality risk factors remains unclear. Repeated assessments are required to take into account symptom fluctuation and de novo symptom appearance. The study objective was to evaluate mortality in relation to three urinary storage symptoms—urgency, daytime frequency, and nocturia—in middle-aged and elderly men, considering also other time-varying factors during follow-up.
A mail survey of a population-based cohort of men initially aged 50, 60, and 70 years was conducted in Finland in 1994, 1999, 2004, and 2009. The questionnaire included assessments of LUTS based on the Danish Prostatic Symptom Score and comorbidities. The men were followed up for mortality through the population registry through 2014. LUTS-related hazard ratios (HR) were analyzed with time-dependent Cox regression adjusted for the year of birth and comorbidities using variable values updated every 5 years. Sensitivity analyses were conducted using values of all variables fixed to the baseline assessment of 1994.
Of the 1332 eligible men with data on LUTS from each preceding survey, 514 (38.6%) died during the 21-year follow-up. In time-dependent analyses, daytime frequency, and nocturia were significantly associated with increased mortality: the adjusted HR was 1.42 (95% CI 1.11–1.83) for daytime frequency, 1.38 (1.07–1.79) for nocturia and 1.19 (0.94–1.50) for urgency. In sensitivity analyses with fixed baseline characteristics, only nocturia was suggestively associated with an increased risk of death: the adjusted HR was 1.09 (0.84–1.42) for daytime frequency, 1.41 (0.99–2.02) for nocturia and 0.94 (0.52–1.68) for urgency.
Among aging men, LUTS are more accurate predictors of short-term than longer-term mortality risk. Repeated assessments are needed to detect clinically relevant and persistent symptoms, often associated with ill health. Accordingly, men with daytime frequency or nocturia exhibit a 1.4-fold risk of death and therefore, should be evaluated for underlying comorbidity.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $24.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.
Taylor J, Harrison SC, Assassa RP, McGrother CW. The pattern and progression of lower urinary tract symptoms after transurethral prostatectomy compared with those seen in the general population. Eur Urol. 2007;51:1023–9.
Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, et al. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014;84:675–80.
Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. 2009;103(Suppl 3):24–32.
Smith DP, Weber MF, Soga K, Korda RJ, Tikellis G, Patel MI, et al. Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men: population-based study. PLoS ONE. 2014;9:e109278.
Gacci M, Corona G, Sebastianelli A, Serni S, De Nunzio C, Maggi M, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol. 2016;70:788–96.
Bouwman II, Voskamp MJ, Kollen BJ, Nijman RJ, van der Heide WK, Blanker MH. Do lower urinary tract symptoms predict cardiovascular diseases in older men? A systematic review and meta-analysis. World J Urol. 2015;33:1911–20.
Pesonen JS, Cartwright R, Santti H, Mangera A, Tähtinen RM, Griebling TL, et al. The impact of nocturia on mortality: a systematic review and meta-analysis. Neurourol Urodyn 2014;33:783–4.
Pesonen JS, Cartwright R, Mangera A, Santti H, Griebling TL, Pryalukhin AE, et al. Incidence and remission of nocturia: a systematic review and meta-analysis. Eur Urol. 2016;70:372–81.
Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol. 1998;34:325–32.
Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur Urol. 2010;58:149–56.
Koskimaki J, Hakama M, Huhtala H, Tammela TL. Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol. 1998;81:364–9.
Häkkinen JT, Hakama M, Shiri R, Auvinen A, Tammela TL, Koskimaki J. Incidence of nocturia in 50 to 80-year-old Finnish men. J Urol. 2006;176:2541.
Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol. 1995;76:451–8.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.
Little RJ, Rubin DB. Statistical analysis with missing data. 2nd ed. New York: Wiley; 2002.
Nuotio M, Tammela TL, Luukkaala T, Jylha M. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res. 2002;14:412–9.
Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol. 2011;185:571–7.
Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(Suppl 3):12–23.
Chong C, Fong L, Lai R, Koh YT, Lau WK, Hartman M, et al. The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study. Prostate Cancer Prostatic Dis. 2012;15:273–7.
Michel MC, de la Rosette JJ. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int. 2005;96(Suppl 1):37–42.
Drake MJ. Should nocturia not be called a lower urinary tract symptom? Eur Urol. 2015;67:289–90.
Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006;50:581–6.
Kim S, Jeong JY, Choi YJ, Kim DH, Lee WK, Lee SH, et al. Association between lower urinary tract symptoms and vascular risk factors in aging men: the Hallym Aging Study. Korean J Urol. 2010;51:477–82.
He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis. 2016;19:7–13.
Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157–62.
Chiu AF, Liao CH, Wang CC, Wang JH, Tsai CH, Kuo HC. High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms. Urology. 2012;79:260–5.
Obayashi K, Saeki K, Kurumatani N. Independent associations between nocturia and nighttime blood pressure/dipping in elderly individuals: the HEIJO-KYO Cohort. J Am Geriatr Soc. 2015;63:733–8.
Noguchi N, Chan L, Cumming RG, Blyth FM, Naganathan V. A systematic review of the association between lower urinary tract symptoms and falls, injuries, and fractures in community-dwelling older men. Aging Male. 2016;19:168–74.
Funding from State Research Funding of the Tampere University Hospital (Finland) was used for collection of the data.
Conflict of interest
J.A. has attended scientific congress as a guest for Sanofi. J.P. has received an unrestricted grant from Ferring, a lecture honorarium from Astellas, Merck and Orion and attended scientific congresses as a guest for Astellas, Novartis, and Orion. J.H. has attended scientific congresses as a guest for Astellas and Orion. T.L.J.T. worked as a consultant for Astellas, Orion Pharma, Bayer AG, Jansse-Cilag and as an investigator in clinical trials sponsored by Medivation, Orion Pharma, Bayer AG, Pfizer, Janssen-Cilag and Lidds Ab. A.A. has been expert advisor for Epid Research Inc.
About this article
Cite this article
Åkerla, J., Pesonen, J.S., Pöyhönen, A. et al. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis 22, 317–323 (2019). https://doi.org/10.1038/s41391-018-0108-z